Literature DB >> 11737386

Antiretroviral treatment of central nervous system HIV-1 infection: a review.

M Gisslén1, L Hagberg.   

Abstract

HIV-1 infects the central nervous system (CNS) and it has been feared that the CNS may be a sanctuary site where HIV-1 could hide and continue to replicate despite otherwise effective antiretroviral treatment. Neurological HIV-1 related symptoms, cerebrospinal fluid (CSF) viral load, intrathecal immunoactivation and CSF drug concentration measurements are considered in this review of antiretroviral treatment effects on CNS HIV-1 infection. We conclude that antiretroviral combination treatment regimens improve neurocognitive symptoms in HIV-1 infection and substantially lower CSF viral load. The threat of an increasing number of patients with neurological symptoms and continued HIV-1 replication in the brain despite otherwise effective antiretroviral therapy has not yet proved to be a problem. It is, however, important to keep this potential risk in mind, and more longitudinal prospective studies addressing the issue of antiretroviral treatment effects on CNS HIV-1 infection are needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737386     DOI: 10.1046/j.1468-1293.2001.00056.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  9 in total

1.  Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.

Authors:  Aylin Yilmaz; Victoria Watson; Laura Dickinson; David Back
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  Impact of HIV and Atiretroviral Therapy on Neurocognitive Outcomes Among School-Aged Children.

Authors:  Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Joseph Kagaayi; Godfrey Kigozi; David Serwadda; Avy Violari; Ronald H Gray
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

3.  Suppression of HIV-1 Infectivity by Human Glioma Cells.

Authors:  Sheikh Ariful Hoque; Atsushi Tanaka; Salequl Islam; Gias Uddin Ahsan; Atsushi Jinno-Oue; Hiroo Hoshino
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

Review 4.  Effects of antiretroviral therapy on cognitive impairment.

Authors:  Kevin J Liner; Colin D Hall; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2008-05       Impact factor: 5.071

5.  A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS.

Authors:  Lance O Bauer
Journal:  Brain Cogn       Date:  2008-01-28       Impact factor: 2.310

6.  Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

Authors:  Patrick R Harrington; Gretja Schnell; Scott L Letendre; Kimberly Ritola; Kevin Robertson; Colin Hall; Christina L Burch; Cassandra B Jabara; Dominic T Moore; Ronald J Ellis; Richard W Price; Ronald Swanstrom
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

7.  CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).

Authors:  Fatih M Uckun; Larisa Rustamova; Alexei O Vassilev; Heather E Tibbles; Alexander S Petkevich
Journal:  BMC Infect Dis       Date:  2005-02-22       Impact factor: 3.090

8.  Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.

Authors:  Joome Suh; Elizabeth Sinclair; Julia Peterson; Evelyn Lee; Tassos C Kyriakides; Fang-Yong Li; Lars Hagberg; Dietmar Fuchs; Richard W Price; Magnus Gisslen; Serena Spudich
Journal:  J Neuroinflammation       Date:  2014-12-03       Impact factor: 8.322

9.  Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus.

Authors:  Fatih M Uckun; Alexander S Petkevich; Alexei O Vassilev; Heather E Tibbles; Leonid Titov
Journal:  BMC Infect Dis       Date:  2004-01-13       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.